Platelet glycoprotein IIb/IIIa integrin blockade in coronary artery disease: Current state of the art

Journal of Thrombosis and Thrombolysis

Volumn 4, Issue 3-4, 1997, Pages 431-439

  Tan, Huay Cheem ^a   Harrington, Robert A ^a   Tcheng, James E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Coronary angioplasty; Glycoprotein IIb IIa inhibition; Platelets

Indexed keywords

FIBRINOGEN RECEPTOR; GLYCOPROTEIN; INTEGRIN; THROMBOCYTE RECEPTOR;

ARTICLE; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HEART MUSCLE ISCHEMIA; PATHOGENESIS; PRIORITY JOURNAL; THROMBOCYTE; THROMBOGENESIS;

EID: 0030840429     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008809702729     Document Type: Article

References (45)

1. Fuster V, Badimon L, Badimon JJ, Chesebro J. The pathogenesis of coronary artery disease and the acute coronary syndromes. New Engl J Med 1992;326:242-250.
2. Ferguson JJ, Barasch E, Wilson JM, et al. Relation of clinical outcome to dissection and thrombus formation during coronary angioplasty. J Invasive Cardiol 1995;7:2-10.
3. Cowley MJ, Dorros G, Kelsey SF, Van Raden M, Detre KM. Acute coronary events associated with percutaneous transluminal coronary angioplasty. Am J Cardiol 1984;53:12C-16C.
4. Detre KM, Holmes DR Jr, Holubkov R, et al. Incidence of periprocedural occlusion: The 1985-1986 National Heart, Lung and Blood Institute PTCA Registry. Circulation 1990; 82:739-750.
5. Lincoff AM, Popma JJ, Ellis SG, et al. Abrupt vessel closure complicating coronary angioplasty: Clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992;19:926-935.
6. Poncz M, Eisman R, Heidenreich R, et al. Structure of the platelet membrane glycoprotein IIb. J Biol Chem 1987;262: 8476-8482.
7. Plow EF, McEver RP, Coller BS, Woods VL Jr, Margurie GA, Ginsburg MH. Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor and thrombospondin on thrombin-stimulated human platelets. Blood 1985;66:724-727.
8. Gralnick HR, Williams SB, Coller BS. Fibrinogen competes with von Willebrand factor for binding to the glycoprotein IIb/IIIa complex when platelets are stimulated with thrombin. Blood 1984;64:797-800.
9. Phillips DR, Charo IF, Parisi LV, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood 1988;71:831-843.
10. Chesebro JH, Lam JYT, Badimon L, Fuster V. Restenosis after arterial angioplasty: a hemorrheologic response to injury. Am J Cardiol 1987;60:10B-16B.
11. George JN, Caen JP, Nurden AT. Glanzmann thrombasthenia: The spectrum of clinical disease. Blood 1990;75:1383-1395.
12. Coller BS. Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: Defective platelet-fibrinogen interaction in thrombasthenia. Blood 1980;55:169-178.
13. Coller BS. A new murine monoclonal antibody reports an activation dependent change in the conformation and/or microenvironment of the glycoprotein IIb/IIIa complex. J Clin Invest 1985;76:101-108.
14. Coller BS, Scudder LE, Beer J. Monoclonal antibodies to platelet glycoprotein IIb/IIIa receptor as antithrombotic agents. Ann NY Acad Sci 1991;614:193-213.
15. Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 1986;68:783-786.
16. Fitzgerald DJ, Hanson M, Fitzgerald GA. Systemic lysis protects against the effects of platelet activation during coronary thrombolysis. J Clin Invest 1991;88:1589-1595.
17. Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation 1988;77:670-677.
18. Yasuda T, Gold HK, Fallon JT, Leinbach RC, Guerrero JL. Monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988;81:1284-1291.
19. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-1764.
20. Scarborough RM, Rose JW, Hsu MA, Phillips DR, Fried VA. Barbourin: A GP IIb/IIIa specific integrin antagonist from the venom of Sistrurus M barbouri. J Biol Chem 1991;266: 9359-9362.
21. Barker PL, Bullens S, Bunting S, Burdick DJ, Chan KS. Cyclic RGD peptide analogues as antiplatelet antithrombotics. J Med Chem 1992;35:2040-2048.
22. Steele PM, Chesebro JH, Stanson AW, et al. Balloon angioplasty: Natural history of the pathophysiological response to injury in a pig model. Circ Res 1985;57:105-112.
23. Kaplan AV, Leung LL-K, Leung WH, Grant GW, McDougall IR. Roles of thrombin and platelet membrane glycoprotein IIb/IIIa in platelet-subendothelial deposition after angioplasty in an ex vivo whole artery model. Circulation 1991;84: 1279-1288.
24. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
25. Lefkovits J, Ivanhoe R, Anderson K, Weisman H, Topol EJ, for the EPIC Investigators. Platelet IIb/IIIa receptor inhibition during PTCA for acute myocardial infarction: Insights from the EPIC Trial. Circulation 1994;90:I-564 (abstr).
26. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet 1994;343:881-886.
27. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet GP IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91:2882-2890.
28. Lincoff AM. EPILOG results. Presented at the 45th Annual Scientific Session of the American College of Cardiology, Orlando, Florida, March 24-27,1996.
29. Ferguson JJ. EPILOG and CAPTURE Trials halted because of positive interim results. Circulation 1996;93:637.
30. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin GP IIb/IIIa blocker integrelin in elective coronary intervention. Circulation 1995;91:2151-2157.
31. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide GP IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222-1227.
32. ™ during percutaneous coronary intervention: The IMPACT II Trial. Circulation 1995;92(Suppl I):I-543 (abstr).
33. Teirstein PS, Yakubov SJ, Thel MC, Wildermann N, Kereiakes DJ, et al. Platelet IIb/IIIa blockade with integrilin: atherectomy patients. J Am Coll Cardiol 1996;27: 334A (abstr).
34. Challapalli RM, Eisenberg MJ, Sigmon K, Leimberger J, for the EPIC Investigators. Platelet GP IIb/IIIa monoclonal antibody (c7E3) reduces distal embolization during percutaneous intervention of saphenous vein grafts. Circulation 1995;92:I-607 (abstr).
35. King SB. RESTORE results. Presented at the 45th Annual Scientific Session of the American College of Cardiology, Orlando, Florida, March 24-27, 1996.
36. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody c7E3 Fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993;22:381-389.
37. ™ in acute myocardial infarction: Results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997;95:846-854.
38. Moliterno, Harrington RA, Califf RM. Randomized, placebocontrolled study of lamifiban with thrombolytic therapy for the treatment of acute myocardial infarction: Rationale and design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Study. J Thromb Thrombol 1995;2: 165-169.
39. Simoons ML, de Boer MJ, van den Brand MJ, van Miltenburg AJ, Hoorntje JC. Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994;89:596-603.
40. ™ in unstable angina: A double-blind randomized trial. Circulation 1993;88:I-608 (abstr).
41. Crenshaw BS, Harrington RA, Tcheng JE. Novel antiplatelet agents: The glycoprotein IIb/IIIa inhibitors. Drugs 1995;4:1033-1044.
42. Berkowitz SD, Sane DC, Shavender JH, Sigmon KN, Topol EJ, Califf RM, for the EPIC Study Group. Analysis of the occurrence and clinical significance of thrombocytopenia with c7E3 (abciximab) in the EPIC Trial. J Am Coll Cardiol 1996;27:82A (abstr).
43. Faulds D, Sorkin EM. Abciximab (c7E3 Fab): A review of its pharmacology and therapeutic potential in ischemic heart disease. Drugs 1994;48:583-598.
44. Tcheng JE. Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents. Am Heart J 1995; 130:673-679.
45. Brezina K, Murphy M, Stonner T. Care of the patient receiving ReoPro after angioplasty. J Invas Cardiol 1994;6:38A-42A.